Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03925324 · ClinicalTrials.gov registry record · Phase 2
Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03925324: Clinical Trial Phase 2 study, sponsored by Medstar Health Research Institute.
NCT03925324 is a Phase 2 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03925324, a Phase 2 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
Primary Outcome
Temperature
Interventions
- OTHER Placebo
- BIOLOGICAL Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2021-08-16 |
| Phase | Phase 2 |
Why NCT03925324 stopped before completion
NCT03925324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03925324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03925324 about?
NCT03925324 is a clinical study titled "Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device". A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
What is the current status of trial NCT03925324?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-05-03. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT03925324?
The interventions under investigation include: Placebo (OTHER), Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03925324?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03925324's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI